201 related articles for article (PubMed ID: 29108377)
1. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.
Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X
Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924
[TBL] [Abstract][Full Text] [Related]
3. Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy.
Peng H; Chen L; Zhang J; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
J Cancer; 2017; 8(3):371-377. PubMed ID: 28261337
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II-IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis.
Yang J; Liang ZG; Jiang YT; Chen KH; Li L; Qu S; Zhu XD
Front Oncol; 2021; 11():778836. PubMed ID: 34926289
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
6. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
8. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
[TBL] [Abstract][Full Text] [Related]
9. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
10. Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study.
Xia WX; Liang H; Lv X; Wang L; Ye YF; Ke LR; Xu LH; Guo X; Xiang YQ
Cancer Manag Res; 2019; 11():9813-9827. PubMed ID: 31819619
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
12. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y
Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759
[TBL] [Abstract][Full Text] [Related]
13. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
14. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy reduces target volume drift in patients with locoregionally advanced nasopharyngeal carcinoma undergoing adaptive intensity-modulated radiotherapy: a retrospective cohort study.
Yan D; Yin X; Wang L; Huang L; Tang Q; Cheng K; Yan S
Quant Imaging Med Surg; 2023 Mar; 13(3):1779-1791. PubMed ID: 36915305
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
17. Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma.
Liu SL; Sun XS; Lu ZJ; Chen QY; Lin HX; Tang LQ; Bei JX; Guo L; Mai HQ
Front Oncol; 2020; 10():539321. PubMed ID: 33240805
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study.
Wu LR; Yu HL; Jiang N; Jiang XS; Zong D; Wen J; Huang L; Xie P; Chen W; Wang TT; Gu DY; Yan PW; Yin L; He X
Oncotarget; 2017 Sep; 8(44):76807-76815. PubMed ID: 29100350
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
